Incidence of hepatitis A in Israel following universal immunization of toddlers

JAMA

Volumn 294, Issue 2, 2005, Pages 202-210

  Dagan, Ron ^a,b   Leventhal, Alex ^c   Anis, Emilia ^c   Slater, Paul ^c   Ashur, Yaffa ^d   Shouval, Daniel ^d  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c MINISTRY OF HEALTH   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE;

AGE DISTRIBUTION; ARTICLE; CHILD HEALTH CARE; CLINICAL TRIAL; HEALTH SURVEY; HEPATITIS A; HUMAN; IMMUNIZATION; INCIDENCE; ISRAEL; POPULATION RESEARCH; PRIORITY JOURNAL; TREATMENT OUTCOME; ADOLESCENT; ADULT; AGED; CHILD; INFANT; MIDDLE AGED; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; STATISTICS; VACCINATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; ISRAEL; MIDDLE AGED; VACCINATION;

EID: 22144476534     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.2.202     Document Type: Article

References (44)

1. Gust ID. Epidemiological patterns of hepatitis A in different parts of the world. Vaccine. 1992;10(suppl 1):S56-S58.
2. Hadler SC. Global impact of hepatitis A virus infection changing patterns. In: Hollinger F, Lemon S, Margolis H, eds. Viral Hepatitis and Liver Disease: Proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: Contemporary Issues and Future Prospects. Baltimore, Md: Williams & Wilkins; 1991:14-20.
3. Yao G. Clinical spectrum and natural history of viral hepatitis A in 1988 Shanghai epidemic. In: Hollinger F, Lemon S, Margolis H, eds. Viral Hepatitis and Liver Disease: Contemporary Issues and Future Prospects: Proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease. Baltimore, Md: Williams & Wilkins; 1990.
4. Anis E, Leventhal A, Roitman M, Slater PE. Introduction of routine hepatitis A immunization in Israel - the first in the world [in Hebrew]. Harefuah. 2000;138:177-180, 272.
5. Green MS, Aharonowitz G, Shohat T, Levine R, Anis E, Slater PE. The changing epidemiology of viral hepatitis A in Israel. Isr Med Assoc J. 2001;3:347-351.
6. Zamir C, Rishpon S, Zamir D, Leventhal A, Rimon N, Ben-Porath E. Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine. Eur J Clin Microbiol Infect Dis. 2001;20:185-187.
7. Israel Ministry of Health. Report of the Information and Computing Services Department. Jerusalem: Israel Ministry of Health; 1999.
8. Green MS, Block C, Slater PE. Rise in the incidence of viral hepatitis in Israel despite improved socioeconomic conditions. Rev Infect Dis. 1989;11:464-469.
9. Israeli Center for Disease Control. Surveillance for the Evaluation of Immunity Against Infectious Hepatitis A in Children in Israel. Jerusalem: Israel Ministry of Health; 1999. No. 7001.
10. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999;48(RR-12):1-37.
11. Staes C, Schlenker T, Risk I, et al. Source of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics. 2000;106:e54.
12. Hadler S, Webster H, Erben J, Swanson J, Maynard J. Hepatitis A in day-care centers: a community-wide assessment. N Engl J Med. 1980;302:1222-1227.
13. Ginsber GM, Slater PE, Shouval D. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in areas of intermediate endemicity. J Hepatol. 2001;34:92-99.
14. Lerman Y, Chodik G, Aloni H, Ashkenazi S. How valid is the official data from the Health Department on reported morbidity in Israel? hepatitis A as an example [in Hebrew]. Harefuah. 1999;136:441-445, 514-515.
15. Israel Central Bureau of Statistics. Statistical Abstract of Israel No. 54. Jerusalem: Israel Central Bureau of Statistics; 2003.
16. Shouval D, Ashur Y, Adler R, et al. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. Vaccine. 1993;11(suppl 1):S9-S14.
17. World Health Organization. Global disease elimination and eradication as public health strategies. Bull World Health Organ. 1998;76:94-102.
18. Andre F, Van Damme P, Safary A, Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines. 2002;1:9-23.
19. Werzberger A, Mensch B, Nalin DR, Kuter BJ. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA. Vaccine. 2002;20:1699-1701.
20. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis. 1995;171(suppl 1):S44-S49.
21. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994;271:1328-1334.
22. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med. 1992;327:453-457.
23. McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med. 1996;150:733-739.
24. Centers for Disease Control and Prevention. Hepatitis A vaccination programs in communities with high rates of hepatitis A.MMWRMorb Mortal Wkly Rep. 1997;46:600-603.
25. Craig AS, Sockwell DC, Schaffner W, et al. Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A. Clin Infect Dis. 1998;27:531-535.
26. Allard R, Beauchemin J, Bedard L, Dion R, Tremblay M, Carsley J. Hepatitis A vaccination during an outbreak among gay men in Montreal, Canada, 1995-1997. J Epidemiol Community Health. 2001;55:251-256.
27. Craig AS, Schaffner W. Prevention of hepatitis A with the hepatitis A vaccine. N Engl J Med. 2004;350:476-481.
28. Averhoff F, Shapiro CN, Bell BP, et al. Control of hepatitis A through routine vaccination of children. JAMA. 2001;286:2968-2973.
29. Bialek SR, Thoroughman DA, Hu D, et al. Hepatitis A incidence and hepatitis A vaccination among American Indians and Alaska Natives, 1990-2001. Am J Public Health. 2004;94:996-1001.
30. Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics. 2002;109:839-845.
31. Koff RS. The case for routine childhood vaccination against hepatitis A. N Engl J Med. 1999;340:644-645.
32. Jacobs RJ, Greenberg DP, Koff RS, Saab S, Meyerhoff AS. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J. 2003;22:904-914.
33. Meyerhoff AS, Jacobs RJ. Transmission of hepatitis A through household contact. J Viral Hepat. 2001;8:454-458.
34. Smith PF, Grabau JC, Werzberger A, et al. The role of young children in a community-wide outbreak of hepatitis A. Epidemiol Infect. 1997;118:243-252.
35. Rosenblum LS, Villarino ME, Nainan OV, et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis. 1991;164:476-482.
36. Wiens BL, Bohidar NR, Pigeon JG, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol. 1996;49:235-241.
37. Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and longterm antibody persistence. J Med Virol. 1994;44:446-451.
38. Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol. 2002;68:489-493.
39. Reisler DM, Brachott D, Mosley JW. Viral hepatitis in Israel: morbidity and mortality data. Am J Epidemiol. 1970;92:62-72.
40. Fattal B. Infectious disease morbidity in Kibbutzim [in Hebrew]. Harefuah. 1988;115:111-115.
41. Vogt RL, LaRue D, Klaucke DN, Jillson DA. Comparison of an active and passive surveillance system of primary care providers for hepatitis, measles, rubella, and salmonellosis in Vermont. Am J Public Health. 1983;73:795-797.
42. Levy BS, Mature J, Washburn JW. Intensive hepatitis surveillance in Minnesota: methods and results. Am J Epidemiol. 1977;105:127-134.
43. Alter MJ, Mares A, Hadler SC, Maynard JE. The effect of underreporting on the apparent incidence and epidemiology of acute viral hepatitis. Am J Epidemiol. 1987;125:133-139.
44. Behrens RH, Roberts JA. Is travel prophylaxis worth while? economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers. BMJ. 1994;309:918-922.